Equities research analysts forecast that Kalvista Pharmaceuticals Inc (NASDAQ:KALV) will report earnings of ($0.52) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Kalvista Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.62) and the highest is ($0.41). Kalvista Pharmaceuticals reported earnings of ($0.50) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 4%. The company is expected to report its next quarterly earnings report on Thursday, December 13th.
On average, analysts expect that Kalvista Pharmaceuticals will report full-year earnings of ($2.11) per share for the current year, with EPS estimates ranging from ($2.79) to ($1.69). For the next year, analysts expect that the business will post earnings of ($3.59) per share. Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Kalvista Pharmaceuticals.
Kalvista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.14). Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. The company had revenue of $3.72 million during the quarter, compared to the consensus estimate of $4.11 million.
A number of analysts have recently commented on the stock. BidaskClub upgraded shares of Kalvista Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday. Stifel Nicolaus initiated coverage on shares of Kalvista Pharmaceuticals in a research note on Monday, October 15th. They issued a “buy” rating for the company. Cantor Fitzgerald set a $32.00 target price on shares of Kalvista Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 3rd. Zacks Investment Research lowered shares of Kalvista Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Thursday, September 20th. Finally, ValuEngine upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the stock. Kalvista Pharmaceuticals has an average rating of “Buy” and an average target price of $23.67.
In other Kalvista Pharmaceuticals news, Director Albert Cha bought 1,058,824 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $18,000,008.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 49.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in KALV. Spark Investment Management LLC purchased a new position in Kalvista Pharmaceuticals during the second quarter valued at approximately $108,000. BlackRock Inc. lifted its holdings in Kalvista Pharmaceuticals by 203.8% during the second quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 10,871 shares in the last quarter. DRW Securities LLC lifted its holdings in Kalvista Pharmaceuticals by 37.3% during the second quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock valued at $167,000 after purchasing an additional 5,600 shares in the last quarter. Stanley Laman Group Ltd. lifted its holdings in Kalvista Pharmaceuticals by 48.3% during the second quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock valued at $545,000 after purchasing an additional 21,861 shares in the last quarter. Finally, Interwest Venture Management Co. lifted its holdings in Kalvista Pharmaceuticals by 17.8% during the third quarter. Interwest Venture Management Co. now owns 388,766 shares of the specialty pharmaceutical company’s stock valued at $8,596,000 after purchasing an additional 58,824 shares in the last quarter. Institutional investors own 37.13% of the company’s stock.
Shares of KALV stock remained flat at $$19.77 during trading hours on Friday. 106,732 shares of the stock were exchanged, compared to its average volume of 129,879. Kalvista Pharmaceuticals has a 52-week low of $7.73 and a 52-week high of $23.97. The company has a market capitalization of $339.63 million, a price-to-earnings ratio of -12.92 and a beta of 3.02.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Recommended Story: Asset Allocation and Your Retirement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.